Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cogent Biosciences Inc's Business Segments
Cogent Biosciences Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Latestage Development
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Latestage Development0%
- Early Stage Preclinical and Discovery Programs0%
- Research and Development Personnel Related0%
- Research and Development Software Facilities and Other Strategic Support0%
- Other Operational Infrastructure and Advisory Support0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Latestage Development | - | - |
| Early Stage Preclinical and Discovery Programs | - | - |
| Research and Development Personnel Related | - | - |
2 more segments available
Sign in to unlock the full Cogent Biosciences Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Latestage Development0%
- Early Stage Preclinical and Discovery Programs0%
- Research and Development Personnel Related0%
- Research and Development Software Facilities and Other Strategic Support0%
- Other Operational Infrastructure and Advisory Support0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Latestage Development | - | - |
| Early Stage Preclinical and Discovery Programs | - | - |
| Research and Development Personnel Related | - | - |
2 more segments available
Sign in to unlock the full Cogent Biosciences Inc dataset.
Description of Cogent Biosciences Inc
Cogent Biosciences Inc is a biotechnology company focused on the development of precision therapies for genetically driven diseases. The company is headquartered in Cambridge, Massachusetts, and was founded in 2015 by Dr. Jeffrey A. Chodakewitz and Dr. Alan F. Ezekowitz.
Cogent Biosciences is primarily engaged in the discovery, development, and commercialization of small molecule therapeutics targeting cancer and other serious diseases. The company's therapeutic approach is based on a deep understanding of the underlying molecular drivers of diseases, with a particular focus on target molecules and pathways that are genetically implicated in the development and progression of diseases.
One of the key areas of focus for Cogent Biosciences is the development of therapies for patients with genetically defined oncology indications. The company's lead product candidate is PLX9486, a selective inhibitor of KIT and FLT3-ITD mutations, which are known to play a role in the development of certain types of cancer. PLX9486 has shown promising preclinical and early clinical data, demonstrating its ability to inhibit tumor growth and delay disease progression in patients harboring these mutations.
Beyond oncology, Cogent Biosciences is also actively exploring therapeutic opportunities in other disease areas driven by genetic mutations. The company has developed a proprietary drug discovery platform called KinomeCore, which leverages advanced computational and structural biology approaches to identify and develop small molecules targeting kinases, a class of proteins involved in cell signaling pathways. This platform enables the company to efficiently identify and validate novel drug targets, accelerating the development of precision therapies for various genetic diseases.
In addition to its internal pipeline, Cogent Biosciences actively seeks collaborations and partnerships with other biopharmaceutical companies and academic institutions to further advance its research and development efforts. The company aims to leverage external expertise and resources to accelerate the translation of its discoveries into novel treatments for patients.
Cogent Biosciences has a team of experienced scientists, researchers, and business professionals who are dedicated to advancing the development of precision therapies. The company has established a strong intellectual property portfolio, including patents covering its novel small molecule compounds, drug discovery platform, and methods for treating various diseases.
Overall, Cogent Biosciences Inc is a biotechnology company focused on the development of precision therapies for genetically driven diseases. With its innovative drug discovery platform and promising lead candidate, the company is well-positioned to make significant contributions to the field of precision medicine and improve patient outcomes.
Cogent Biosciences is primarily engaged in the discovery, development, and commercialization of small molecule therapeutics targeting cancer and other serious diseases. The company's therapeutic approach is based on a deep understanding of the underlying molecular drivers of diseases, with a particular focus on target molecules and pathways that are genetically implicated in the development and progression of diseases.
One of the key areas of focus for Cogent Biosciences is the development of therapies for patients with genetically defined oncology indications. The company's lead product candidate is PLX9486, a selective inhibitor of KIT and FLT3-ITD mutations, which are known to play a role in the development of certain types of cancer. PLX9486 has shown promising preclinical and early clinical data, demonstrating its ability to inhibit tumor growth and delay disease progression in patients harboring these mutations.
Beyond oncology, Cogent Biosciences is also actively exploring therapeutic opportunities in other disease areas driven by genetic mutations. The company has developed a proprietary drug discovery platform called KinomeCore, which leverages advanced computational and structural biology approaches to identify and develop small molecules targeting kinases, a class of proteins involved in cell signaling pathways. This platform enables the company to efficiently identify and validate novel drug targets, accelerating the development of precision therapies for various genetic diseases.
In addition to its internal pipeline, Cogent Biosciences actively seeks collaborations and partnerships with other biopharmaceutical companies and academic institutions to further advance its research and development efforts. The company aims to leverage external expertise and resources to accelerate the translation of its discoveries into novel treatments for patients.
Cogent Biosciences has a team of experienced scientists, researchers, and business professionals who are dedicated to advancing the development of precision therapies. The company has established a strong intellectual property portfolio, including patents covering its novel small molecule compounds, drug discovery platform, and methods for treating various diseases.
Overall, Cogent Biosciences Inc is a biotechnology company focused on the development of precision therapies for genetically driven diseases. With its innovative drug discovery platform and promising lead candidate, the company is well-positioned to make significant contributions to the field of precision medicine and improve patient outcomes.
Cogent Biosciences Inc. is a biotechnology company that specializes in the development and commercialization of innovative therapies for genetically defined cancers and rare diseases. The company focuses on addressing the needs of patients with significant unmet medical needs by leveraging advanced technologies and a deep understanding of disease biology. Here’s a detailed exploration of the segments, products, and services that Cogent Biosciences Inc. offers:
Key Segments
1. Oncology:
- Cogents primary focus is on the oncology segment, where it develops targeted therapies for specific cancer types driven by genetic mutations. The oncology pipeline is designed to address cancers that have not seen significant advancements in treatment, particularly those with specific genetic aberrations.
2. Rare Diseases:
- In addition to its oncology focus, Cogent is also actively developing therapies for rare diseases. This segment involves understanding the genetic underpinnings of certain rare conditions and creating targeted treatments that aim to improve patient outcomes.
Products
1. Therapeutics:
- Targeted Therapies: Cogent is known for developing precision medicines that are tailored to specific genetic mutations found in tumors. These therapies are designed to inhibit the pathways that promote tumor growth and survival in patients with these genetic profiles.
- Small Molecule Inhibitors: The company has pioneered several investigational small molecule drugs aimed at specific targets in cancer cells. These molecules are designed to modulate the activity of proteins that play critical roles in cancer progression.
- Combination Therapies: Cogent’s product pipeline includes various strategies for combination therapies that enhance the efficacy of existing treatments or target multiple pathways in cancer biology.
2. Investigational Drugs:
- Cogent Biosciences has multiple investigational drugs in clinical trials, indicating its commitment to advancing new therapies through rigorous testing. These investigational therapies are designed to provide new options for patients with few available treatments.
3. Clinical Programs:
- The companys clinical development programs target specific populations, qualifying patients based on genetic testing to optimize treatment effectiveness. These programs often operate in phased clinical trial environments, progressing through staged evaluations of safety, tolerability, and efficacy.
Services
1. Genetic Profiling and Testing:
- To support its drug development efforts and ensure that patients receive the most appropriate therapies, Cogent Biosciences is involved in initiatives around genetic testing and profiling. This process allows for the identification of specific mutations that could be targeted by its therapies.
2. Collaborative Research:
- Cogent engages in collaborations with academic institutions and research organizations to advance understanding of various genetic mutations and their roles in cancers and rare diseases. These partnerships can facilitate the development of innovative therapeutic approaches.
3. Patient Support Programs:
- Through various initiatives, Cogent aims to provide support to patients and healthcare providers to navigate treatment options, access investigational therapies, and understand the implications of genetic testing.
4. Regulatory Support and Advocacy:
- The company actively engages with regulatory agencies to ensure its products are developed in compliance with established guidelines and to advocate for policies that support patient access to novel therapies.
Research & Development
Cogent invests heavily in R&D to discover and develop new therapeutic candidates. The R&D activities are characterized by:
- Innovation in Drug Discovery: Utilizing cutting-edge technologies and methodologies, including genomics, to identify new therapeutic targets and develop candidate molecules.
- Clinical Trials: Administering and overseeing clinical trials to evaluate the safety and efficacy of its investigational products.
- Data Analytics: Leveraging data analysis tools to understand patient responses and refine treatment strategies.
Market Position
Cogent Biosciences operates within a highly competitive biotech landscape, focusing on niche segments where tailored therapies can lead to significant advancements in patient care. The combination of a strong pipeline, targeted approach to treatment, and commitment to scientific excellence positions the company to potentially make a substantial impact in the realms of oncology and rare diseases.
Conclusion
In summary, Cogent Biosciences Inc. offers a range of products and services that focus on targeted therapeutics for genetically defined cancers and rare diseases. Its commitment to innovation, R&D, and patient-centered services underscores its role as a key player in the biotechnology industry, aiming to address critical unmet medical needs.
Key Segments
1. Oncology:
- Cogents primary focus is on the oncology segment, where it develops targeted therapies for specific cancer types driven by genetic mutations. The oncology pipeline is designed to address cancers that have not seen significant advancements in treatment, particularly those with specific genetic aberrations.
2. Rare Diseases:
- In addition to its oncology focus, Cogent is also actively developing therapies for rare diseases. This segment involves understanding the genetic underpinnings of certain rare conditions and creating targeted treatments that aim to improve patient outcomes.
Products
1. Therapeutics:
- Targeted Therapies: Cogent is known for developing precision medicines that are tailored to specific genetic mutations found in tumors. These therapies are designed to inhibit the pathways that promote tumor growth and survival in patients with these genetic profiles.
- Small Molecule Inhibitors: The company has pioneered several investigational small molecule drugs aimed at specific targets in cancer cells. These molecules are designed to modulate the activity of proteins that play critical roles in cancer progression.
- Combination Therapies: Cogent’s product pipeline includes various strategies for combination therapies that enhance the efficacy of existing treatments or target multiple pathways in cancer biology.
2. Investigational Drugs:
- Cogent Biosciences has multiple investigational drugs in clinical trials, indicating its commitment to advancing new therapies through rigorous testing. These investigational therapies are designed to provide new options for patients with few available treatments.
3. Clinical Programs:
- The companys clinical development programs target specific populations, qualifying patients based on genetic testing to optimize treatment effectiveness. These programs often operate in phased clinical trial environments, progressing through staged evaluations of safety, tolerability, and efficacy.
Services
1. Genetic Profiling and Testing:
- To support its drug development efforts and ensure that patients receive the most appropriate therapies, Cogent Biosciences is involved in initiatives around genetic testing and profiling. This process allows for the identification of specific mutations that could be targeted by its therapies.
2. Collaborative Research:
- Cogent engages in collaborations with academic institutions and research organizations to advance understanding of various genetic mutations and their roles in cancers and rare diseases. These partnerships can facilitate the development of innovative therapeutic approaches.
3. Patient Support Programs:
- Through various initiatives, Cogent aims to provide support to patients and healthcare providers to navigate treatment options, access investigational therapies, and understand the implications of genetic testing.
4. Regulatory Support and Advocacy:
- The company actively engages with regulatory agencies to ensure its products are developed in compliance with established guidelines and to advocate for policies that support patient access to novel therapies.
Research & Development
Cogent invests heavily in R&D to discover and develop new therapeutic candidates. The R&D activities are characterized by:
- Innovation in Drug Discovery: Utilizing cutting-edge technologies and methodologies, including genomics, to identify new therapeutic targets and develop candidate molecules.
- Clinical Trials: Administering and overseeing clinical trials to evaluate the safety and efficacy of its investigational products.
- Data Analytics: Leveraging data analysis tools to understand patient responses and refine treatment strategies.
Market Position
Cogent Biosciences operates within a highly competitive biotech landscape, focusing on niche segments where tailored therapies can lead to significant advancements in patient care. The combination of a strong pipeline, targeted approach to treatment, and commitment to scientific excellence positions the company to potentially make a substantial impact in the realms of oncology and rare diseases.
Conclusion
In summary, Cogent Biosciences Inc. offers a range of products and services that focus on targeted therapeutics for genetically defined cancers and rare diseases. Its commitment to innovation, R&D, and patient-centered services underscores its role as a key player in the biotechnology industry, aiming to address critical unmet medical needs.